今天是:
滚动公告:
 
左侧链接1  

 
王涛
2011-09-08

点击查看原图

    名:王涛                                族:                              出生年月:19769     

学历学位:博士                            称:副教授                      政治面貌:群众(无党派)

学科专业:基础医学           

学历和工作经历:

20057月: 华中科技大学同济医学院博士毕业;

20057-20097月: 武汉大学生命科学学院从事博士后研究工作;

20097月: 安徽医科大学基础医学院从事病理生理学教学科研工作。

研究方向:

1、KRAB类转录因子的克隆,筛选和功能研究。

2、肿瘤药物作用靶点筛选和相关药物的作用机理研究。

代表性科研项目:

国家自然科学基金青年基金项目:人ZNF300基因表达干预对肝癌多药耐药的调控作用(2011.1-----2013.12)。

代表性学术论文:

1、Wang T, Wang XG, Xu JH, Wu XP, Qiu HL, Yi H, Li WX. Overexpression of the human ZNF300 gene enhances growth and metastasis of cancer cells through activating nf-κb pathway. J Cell Mol Med. 2011 Jul 21. doi: 10.1111/j.1582-4934.2011.01388.x. [Epub ahead of print]

2、Xu JH, Wang T, Wang XG, Wu XP, Zhao ZZ, Zhu CG, Qiu HL, Xue L, Shao HJ, Guo MX, Li WX. PU.1 can regulate the ZNF300 promoter in APL-derived promyelocytes HL-60.Leuk Res. 2010 Dec;34(12):1636-46.

3、Yan JT, Wang T, Wang DW. Recombinant adeno-associated virus-mediated human kallikrein gene therapy protects
against hypertensive target organ injuries through inhibiting cell apoptosis. Acta Pharmacol Sin. 2009 Sep;30(9):1253-61.
4、Yan JT, Wang T, Li J, Xiao X, Wang DW. Recombinant adeno-associated virus-mediated human kallikrein gene
therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure. Acta Pharmacol Sin.
2008 Jul;29(7):808-14.
5、Wang T, Hou LB, Liu ZJ, Wang Y, Chen CL, Xiao X, Wang DW. Intramuscular delivery of rAAV-mediated 
kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin.
2007 Dec;28(12):1898-906.
6、Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X, Wang DW. Recombinant adeno-associated 
virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther.
2004 Sep;11(17):1342-50.

联系方式:Emaildtaowang@yahoo.com.cn    办公电话:0551-5161129